Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Carroll, M. J.
Right arrow Articles by Cawthorne, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Carroll, M. J.
Right arrow Articles by Cawthorne, M. A.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes, Vol 34, Issue 11 1198-1204, Copyright © 1985 by American Diabetes Association

ARTICLES

Improved glycemic control in C57Bl/KsJ (db/db) mice after treatment with the thermogenic beta-adrenoceptor agonist, BRL 26830

MJ Carroll, CA Lister, MV Sennitt, N Stewart-Long and MA Cawthorne

BRL 26830, (R*,R*)-(+/-)-methyl-4-(2-[(2-hydroxy-2-phenylethyl)amino]propyl)-benzoa te, is a new type of beta-adrenoceptor receptor agonist that combines antihyperglycemic and thermogenic properties. In C57Bl/KsJ db/db mice, treatment with BRL 26830 (50 mg of the hemifumarate salt/kg diet) decreased blood glucose concentration and normalized water intake. As judged by the normalization of polydipsia, BRL 26830 was effective within 2 days and the effect was maintained throughout a treatment period of up to 11 wk. Treatment of db/db mice with BRL 26830 resulted in an increase in both plasma and pancreatic insulin concentrations and a partial restoration of first-phase insulin secretion by the isolated, perfused pancreas in response to a high (16.7 mM) glucose pulse. Given acutely, BRL 26830 increased energy expenditure in both fed and fasted db/db mice. When given chronically, BRL 26830 increased significantly the dietary and thermoregulatory component of metabolic rate. It is suggested that the antidiabetic and thermogenic properties of BRL 26830 are linked and that blood glucose acts either directly or indirectly as a substrate for thermogenesis.
Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Proc. Natl. Acad. Sci. USAHome page
D. Chen, J. Liao, N. Li, C. Zhou, Q. Liu, G. Wang, R. Zhang, S. Zhang, L. Lin, K. Chen, et al.
From the Cover: A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db/db mice
PNAS, January 16, 2007; 104(3): 943 - 948.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
R. Alemzadeh and K. M. Tushaus
Modulation of Adipoinsular Axis in Prediabetic Zucker Diabetic Fatty Rats by Diazoxide
Endocrinology, December 1, 2004; 145(12): 5476 - 5484.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
V. S. Susulic, L. LaVallette, E. Duzic, L. Chen, D. Shuey, S. K. Karathanasis, and K. E. Steiner
Expression of the Human {beta}3-Adrenergic Receptor Gene in SK-N-MC Cells Is Under the Control of a Distal Enhancer
Endocrinology, May 1, 2001; 142(5): 1935 - 1949.
[Abstract] [Full Text]

Home page
 DiabetesHome page
H. Kato, M. Ohue, K. Kato, A. Nomura, K. Toyosawa, Y. Furutani, S. Kimura, and T. Kadowaki
Mechanism of Amelioration of Insulin Resistance by {beta}3-Adrenoceptor Agonist AJ-9677 in the KK-Ay/Ta Diabetic Obese Mouse Model
Diabetes, January 1, 2001; 50(1): 113 - 122.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 1985 by the American Diabetes Association.